Submitted by dcc on Fri, 2022-12-09 09:22 Study Title: A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior ChemotherapyCIRB: Adult CIRB - Late Phase EmphasisLead Group: AllianceStatus: ActiveReview Status: Available to Open
